Biogen Pharmachem Industries Limited has submitted a regulatory disclosure to BSE Limited regarding the utilization of funds from past capital raises. The disclosure is made pursuant to SEBI Circular CIR/CFD/CMD1/162/2019 dated December 24, 2019, read with Regulation 32(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
The company explicitly states that it does not have any unutilized funds remaining as of September 30, 2026, or as of the disclosure date (November 3, 2026) from any previous public issue, rights issue, preferential issue, or qualified institutional placement (QIP) that may have been undertaken by the company at any time in the past.
Due to the complete utilization of all proceeds from past capital raises, the company confirms that no information is required to be provided by way of Annexure-A as stipulated under the relevant SEBI regulation and circular.
The disclosure was signed by Kelash Bunkar, Whole-time Director of Biogen Pharmachem Industries Limited, and submitted to the Department of Corporate Services at BSE Limited.